The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
Open accessAbstract
Accelerated proliferation of solid tumor and hematologic cancer cells is linked to accelerated transcription of rDNA by the RNA polymerase I (Pol I) enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among tumor suppressors and oncogenes, is required for maintenance of the cancer phenotype and forms the basis for seeking selective inhibitors of Pol I as anticancer therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of RNA Pol I transcription with in vivo activity in tumor growth efficacy models. The preclinical data support the development of CX-5461 as an anticancer drug with potential for activity in several types of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Life on a planet of its own: Regulation of RNA polymerase I transcription in the nucleolus
Grummt, I. (2003) · Genes & Development · doi:10.1101/gad.1098503r · Cited by 540
Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53
Zhai, W., & Comai, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5930-5938.2000 · Cited by 289
p53 represses ribosomal gene transcription
Budde, A., & Grummt, I. (1999) · Oncogene · doi:10.1038/sj.onc.1202402 · Cited by 157
Cited by
A LINE1-Nucleolin Partnership Regulates Early Development and ESC Identity
Percharde, M., Lin, C.-J., Yin, Y., Guan, J., Peixoto, G. A., Bulut-Karslioglu, A., Biechele, S., Huang, B., Shen, X., & Ramalho-Santos, M. (2018) · Cell · doi:10.1016/j.cell.2018.05.043 · Cited by 555
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance
Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4087 · Cited by 300
Bruno, P. M., Lu, M., Dennis, K. A., Inam, H., Moore, C. J., Sheehe, J., Elledge, S. J., Hemann, M. T., & Pritchard, J. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921649117 · Cited by 175
Stec, M. J., Kelly, N. A., Many, G. M., Windham, S. T., Tuggle, S. C., & Bamman, M. M. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00486.2015 · Cited by 161
Metadata
- Authors
- Haddach, M., Schwaebe, M. K., Michaux, J., Nagasawa, J., O'Brien, S. E., Whitten, J. P., Pierre, F., Kerdoncuff, P., Darjania, L., Stansfield, R., Drygin, D., Anderes, K., Proffitt, C., Bliesath, J., Siddiqui-Jain, A., Omori, M., Huser, N., Rice, W. G., & Ryckman, D. M.
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 3
- Issue
- 7
- Pages
- 602-606
- ISSN
- 1948-5875 (ISSN-L)
- OpenAlex
- W2095445604
- Cited by
- 164
- References
- 3
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. https://app.cochat.ai/papers/10.1021/ml300110s
- The paper
- Haddach, M., Schwaebe, M. K., Michaux, J., Nagasawa, J., O'Brien, S. E., Whitten, J. P., Pierre, F., Kerdoncuff, P., Darjania, L., Stansfield, R., Drygin, D., Anderes, K., Proffitt, C., Bliesath, J., Siddiqui-Jain, A., Omori, M., Huser, N., Rice, W. G., & Ryckman, D. M. (2012). Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/ml300110s
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.